463 related articles for article (PubMed ID: 31229240)
1. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
[TBL] [Abstract][Full Text] [Related]
2. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
Healey JH; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; van de Sande M
Clin Orthop Relat Res; 2023 Jan; 481(1):107-116. PubMed ID: 36001000
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
[TBL] [Abstract][Full Text] [Related]
4. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
5. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
Monestime S; Lazaridis D
Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
[TBL] [Abstract][Full Text] [Related]
6. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
7. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
[TBL] [Abstract][Full Text] [Related]
8. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
Van De Sande M; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; Healey JH
Acta Orthop; 2021 Aug; 92(4):493-499. PubMed ID: 33977825
[TBL] [Abstract][Full Text] [Related]
9. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H; Bhadri V; Stacchiotti S; Bauer S; Wagner AJ; van de Sande M; Bernthal NM; López Pousa A; Razak AA; Italiano A; Ahmed M; Le Cesne A; Tinoco G; Boye K; Martín-Broto J; Palmerini E; Tafuto S; Pratap S; Powers BC; Reichardt P; Casado Herráez A; Rutkowski P; Tait C; Zarins F; Harrow B; Sharma MG; Ruiz-Soto R; Sherman ML; Blay JY; Tap WD;
Lancet; 2024 May; ():. PubMed ID: 38843860
[TBL] [Abstract][Full Text] [Related]
10. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
11. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).
Tap W
Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241
[TBL] [Abstract][Full Text] [Related]
12. Pexidartinib: First Approval.
Lamb YN
Drugs; 2019 Nov; 79(16):1805-1812. PubMed ID: 31602563
[TBL] [Abstract][Full Text] [Related]
13. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
14. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
15. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
16. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
[TBL] [Abstract][Full Text] [Related]
17. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
[TBL] [Abstract][Full Text] [Related]
18. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.
Gelderblom H; Cropet C; Chevreau C; Boyle R; Tattersall M; Stacchiotti S; Italiano A; Piperno-Neumann S; Le Cesne A; Ferraresi V; Penel N; Duffaud F; Cassier P; Toulmonde M; Casali P; Taieb S; Guillemaut S; Metzger S; Pérol D; Blay JY
Lancet Oncol; 2018 May; 19(5):639-648. PubMed ID: 29571946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]